In Liberia, it is estimated that at least 46% of the population accesses antimalarials through the private sector. Quality-assured ACTs, however, are generally more expensive than older antimalarials; therefore, the majority of these outlets still stock chloroquine and other monotherapies. According to the 2010–15 national malaria strategic plan, MOHSW is committed to increasing access to prompt and effective treatment.
SIAPS Final Report
